Myosana Therapeutics, Inc. is leading the efforts in developing new gene therapies that will slow skeletal muscle degeneration and heart failure to improve the quality of life, increase longevity and reduce the disease burden of Duchenne muscular dystrophy (DMD) and other neuromuscular diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/22/20 | $1,000,000 | Seed |
CureDuchenne Ventures | undisclosed |
| 01/25/23 | $5,000,000 | Seed |
John Ballantyne Muscular Dystrophy Association Parent Project Muscular Dystrophy | undisclosed |
